Ipamorelin
Also known as: NNC 26-0161
Selective ghrelin-mimetic that triggers GH release without raising cortisol, ACTH, or prolactin. Often stacked with a GHRH analog like CJC-1295. Never administer IV (documented fatality risk), SubQ only.
Pharmacokinetics
- Half-life
- 2 hours
- Time to peak
- 15 min
- Bioavailability
- 100%
- Onset
- 15 min
- Dosing interval
- 24h
Administration
- Primary routes
- SubQ
- Category
- Growth Hormone Secretagogues
Safety Flags
- High immunogenicity
- Contraindicated in cancer history
Storage
- · Requires refrigeration (2–8°C)
- · Temperature sensitive — minimise room-temp exposure
Used in 6 outcome protocols
- Muscle Growth
Optimize muscle protein synthesis and growth hormone release for enhanced muscle development
Safe default: 200mcg · daily · SubQ
- Injury Repair
Accelerate healing of tendons, ligaments, muscles, and other soft tissues
Safe default: 200mcg · daily · SubQ
- Bone Density
Stimulate osteoblast activity and bone formation for improved bone health
Safe default: 200mcg · daily · SubQ
- Increased Strength
Enhance muscular strength through IGF-1 pathway activation
Safe default: 200mcg · daily · SubQ
- Skin Elasticity
Promote collagen synthesis and skin regeneration for improved skin quality
Safe default: 100mcg · daily · SubQ
- Sleep Quality
Improve sleep architecture and quality of rest
Safe default: 100mcg · daily · SubQ
Simulate Ipamorelin
Pinned.life runs a 1-compartment Bateman pharmacokinetic simulation against 38 peptides in real time. Build a stack, see serum-level curves, get warned about peak overlaps and drug-peptide interactions.